Tumor necrosis factor-α upregulates 11β-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-β in HepG2 cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 2, 2009, Pages

  Ignatova, Irena D ^a   Kostadinova, Radina M ^a,b   Goldring, Christopher E ^a,c   Nawrocki, Andrea R ^a,d   Frey, Felix J ^a   Frey, Brigitte M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Institute of Molecular Biology Zürich   (Switzerland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chromatin immunoprecipitation; p38 mitogen activated protein kinase; RNA interference

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEP 2 CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; LIVER CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TRANSIENT TRANSFECTION; UPREGULATION; ANIMAL; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 60849139081     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90531.2008     Document Type: Article

References (62)

1. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105: R11-R17, 1994.
2. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of nonalcoholic fatty liver disease: population based study. Ann Hepatol 6: 161-163, 2007. (Pubitemid 350277193)
3. An J, Sun Y, Rettig MB. Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood 103: 222-228, 2004.
4. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF)-α, and TNF-related apoptosisinducing ligand in prostate cancer. Clin Cancer Res 9: 4537-4545, 2003.
5. Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 87: 5587-5593, 2002. (Pubitemid 36034364)
6. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005. (Pubitemid 40547890)
7. Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, Frey FJ, Langer T, Odermatt A. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35: 89-101, 2005. (Pubitemid 41167628)
8. Balachandran A, Guan H, Sellan M, van Uum S, Yang K. Insulin and dexamethasone dynamically regulate adipocyte 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 149: 4069-4079, 2008.
9. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997. (Pubitemid 27163860)
10. Bjèorntorp P. International Textbook of Obesity. New York: Wiley, 2001.
11. Bottazzi ME, Buzzai M, Zhu X, Desdouets C, Brechot C, Assoian RK. Distinct effects of mitogens and the actin cytoskeleton on CREB and pocket protein phosphorylation control the extent and timing of cyclin A promoter activity. Mol Cell Biol 21: 7607-7616, 2001. (Pubitemid 32988772)
12. Brautigam VM, Frasier C, Nikodemova M, Watters JJ. Purinergic receptor modulation of BV-2 microglial cell activity: potential involvement of p38 MAP kinase and CREB. J Neuroimmunol 166: 113-125, 2005. (Pubitemid 41078772)
13. Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBPβ and C/EBPδ in astrocytes. Glia 29: 91-97, 2000. (Pubitemid 30031137)
14. Carey M, Smale ST. Transcriptional Regulation in Eukaryotes: Concepts, Strategies, and Techniques. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2000.
15. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001. (Pubitemid 32225829)
16. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16: 1037-1044, 2001. (Pubitemid 32467147)
17. 16a.Coyle FM, Taylor NF, Feakins R, Monson JP, Drake WM, Foster GR. Non-alcoholic fatty liver disease is associated with transcriptional dysregulation of 11 beta-hrdroxsteroid dehydrogenase type 1 leading to excess intrahepatic glucocorticoid exposure. Endocrine Abstracts 15: 328, 2008.
18. Day RM, Thiel G, Lum J, Chevere RD, Yang Y, Stevens J, Sibert L, Fanburg BL. Hepatocyte growth factor regulates angiotensin converting enzyme expression. J Biol Chem 279: 8792-8801, 2004. (Pubitemid 38295937)
19. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ. Tumor necrosis factor-α and interleukin-1-β enhance the cortisone/cortisol shuttle. J Exp Med 186: 189-198, 1997. (Pubitemid 27328019)
20. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, Frey FJ. Down-regulation of hepatic and renal 11β-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 114: 175-184, 1998. (Pubitemid 28020967)
21. Fasen K, Cerretti DP, Huynh-Do U. Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway. Traffic 9: 251-266, 2008.
22. Frey FJ. Impaired 11β-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact? Hepatology 44: 795-801, 2006.
23. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585, 1988. (Pubitemid 18263202)
24. Gout J, Tirard J, Thevenon C, Riou JP, Begeot M, Naville D. CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11β-hydroxysteroid dehydrogenase encoding gene in adipose cells. Biochimie 88: 1115-1124, 2006. (Pubitemid 44415208)
25. Handoko K, Yang K, Strutt B, Khalil W, Killinger D. Insulin attenuates the stimulatory effects of tumor necrosis factor-α on 11β- hydroxysteroid dehydrogenase 1 in human adipose stromal cells. J Steroid Biochem Mol Biol 72: 163-168, 2000. (Pubitemid 30207070)
26. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995.
27. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40: 46-54, 2004. (Pubitemid 38868922)
28. Israel N, Gougerot-Pocidalo MA, Aillet F, Virelizier JL. Redox status of cells influences constitutive or induced NF-κB translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol 149: 3386-3393, 1992.
29. Komine M, Rao LS, Kaneko T, Tomic-Canic M, Tamaki K, Freedberg IM, Blumenberg M. Inflammatory versus proliferative processes in epidermis. Tumor necrosis factor-α induces K6b keratin synthesis through a transcriptional complex containing NF-κB and C/EBPβ. J Biol Chem 275: 32077-32088, 2000.
30. Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, Lochs H, Strasburger CJ, Stewart PM, Quinkler M. Hepatic 11β-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis. Clin Endocrinol (Oxf). In press.
31. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387-398, 1999. (Pubitemid 29165293)
32. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor-α and phorbol 12-myristate-13-acetate down-regulate human 11β- hydroxysteroid dehydrogenase type 2 through p50/p50 NF-κB homodimers and Egr-1. FASEB J 19: 650-652, 2005.
33. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924-14929, 1997. (Pubitemid 28041476)
34. Li Z, Clark J, Diehl AM. The liver in obesity and type 2 diabetes mellitus. Clin Liver Dis 6: 867-877, 2002. (Pubitemid 36026452)
35. Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi PV, Lutfy K, Friedman TC. Increased glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes 54: 32-40, 2005. (Pubitemid 40105092)
36. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 167: 533-539, 2000.
37. Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-α levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127: 954-960, 2007.
38. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001. (Pubitemid 33150673)
39. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276: 41293-41300, 2001. (Pubitemid 37373288)
40. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissuemediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931-938, 2004. (Pubitemid 38436604)
41. Morton NM, Seckl JR. 11β-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 36: 146-164, 2008.
42. Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P, Buhler L, Trono D. Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol 43: 1031-1037, 2005. (Pubitemid 41627989)
43. Niehof M, Manns MP, Trautwein C. CREB controls LAP/C/EBPβ transcription. Mol Cell Biol 17: 3600-3613, 1997. (Pubitemid 27281836)
44. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11β-hydroxysteroid dehydrogenase type 2. J Biol Chem 276: 28484-28492, 2001. (Pubitemid 37391561)
45. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101: 7088-7093, 2004. (Pubitemid 38596447)
46. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 87: 2701-2705, 2002. (Pubitemid 34655333)
47. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 273: 29279-29282, 1998. (Pubitemid 28509923)
48. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11β-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 108: 1299-1305, 2001. (Pubitemid 33107757)
49. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86: 1418-1421, 2001. (Pubitemid 32323037)
50. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87: 3330-3336, 2002.
51. Reaven GM. Role of insulin resistance in the pathophysiology of noninsulin dependent diabetes mellitus. Diabetes Metab Rev 9, Suppl 1: 5S-12S, 1993.
52. Sai S, Esteves CL, Kelly V, Michailidou Z, Anderson K, Coll AP, Nakagawa Y, Ohzeki T, Seckl JR, Chapman KE. Glucocorticoid regulation of the promoter of 11β-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-β. Mol Endocrinol 22: 2049-2060, 2008.
53. Sampson MJ, Davies IR, Brown JC, Ivory K, Hughes DA. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 22: 1187-1193, 2002.
54. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 59: 359-393, 2004.
55. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone-> cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84: 1022-1027, 1999. (Pubitemid 29138237)
56. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain A, Hewison M, Stewart PM. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142: 1982-1989, 2001. (Pubitemid 32405956)
57. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 87: 5630-5635, 2002. (Pubitemid 36034370)
58. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-866, 2004. (Pubitemid 39366049)
59. White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK. 11β- Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr Res 41: 25-29, 1997. (Pubitemid 27008631)
60. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR, Chapman KE. C/EBP regulates hepatic transcription of 11β- hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 275: 30232-30239, 2000.
61. Willis D, Zhang Y, Molloy GR. Transcription of brain creatine kinase in U87-MG glioblastoma is modulated by factor AP2. Biochim Biophys Acta 1728: 18-33, 2005. (Pubitemid 40409952)
62. Yin M, Yang SQ, Lin HZ, Lane MD, Chatterjee S, Diehl AM. Tumor necrosis factorα promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes. J Biol Chem 271: 17974-17978, 1996. (Pubitemid 26250781)